...
首页> 外文期刊>Drug discovery today >MCR-1: a promising target for structure-based design of inhibitors to tackle polymyxin resistance
【24h】

MCR-1: a promising target for structure-based design of inhibitors to tackle polymyxin resistance

机译:MCR-1:一种有前途的抑制剂设计抑制剂设计的靶标,以解决多粘菌素抗性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The spread of a novel mobile colistin resistance gene (mcr1) has jeopardised the use of polymyxins, last-resort antibiotics that are used increasingly to treat infections caused by multidrug-resistant (MDR) Gram-negative pathogens. In early 2017, the WHO reported the global spread of mcr1 within a few years after its initial discovery in China. The protein encoded by mcr1 is a putative 60-kDa phosphoethanolamine (pEtN) transferase, MCR-1, and has been studied extensively since its discovery. Herein, we present a comprehensive review of MCR-1 covering its structure, function, and mechanism, to call for the rational drug design of molecular inhibitors of MCR-1 to use in colistin-based combination therapies.
机译:新型移动乳菌素抵抗基因(MCR1)的传播危及了多种辛的使用,越来越多地用于治疗由多药(MDR)革兰氏阴性病原体引起的感染。 2017年初,世卫组织在中国初步发现后几年后报告了MCR1的全球传播。 由MCR1编码的蛋白质是推定的60-KDA磷酸乙醇胺(PETN)转移酶,MCR-1,并且自发现以来已经广泛地研究。 在此,我们对MCR-1进行了全面的审查,涵盖其结构,功能和机制,呼吁MCR-1分子抑制剂的合理药物设计用于基于Colistin的组合疗法。

著录项

  • 来源
    《Drug discovery today》 |2019年第1期|共11页
  • 作者单位

    Univ Auckland Sch Chem Sci Victoria St West Private Bag 92019 Auckland 1142 New Zealand;

    Univ Auckland Sch Chem Sci Victoria St West Private Bag 92019 Auckland 1142 New Zealand;

    Univ Auckland Sch Biol Sci Victoria St West Private Bag 92019 Auckland 1142 New Zealand;

    Univ Auckland Sch Chem Sci Victoria St West Private Bag 92019 Auckland 1142 New Zealand;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号